Juntuo Biopharma

Juntuo Biopharma (君拓生物) is a microbiome therapeutics company and a subsidiary of Xeweijun (未知君) . In August 2022, it announced that its KEX02 live biotherapeutic product, in combination with a PD-1 inhibitor for treating non-small cell lung cancer, had received FDA Investigational New Drug (IND) approval — described in reporting at the time as China's first microbiome live drug pipeline to secure this clearance . The company operates in the broader live biotherapeutic and oncology space, though elsewhere's corpus does not carry more recent updates on its clinical progress beyond this 2022 milestone.